Navigation Links
Access Pharmaceuticals Presents New Data at International Symposium Showing Company's Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
Date:6/26/2008

DALLAS, June 26 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that the Company gave an oral presentation yesterday on its monoclonal antibody product, Angiolix(R), at the 7th International Congress on Recombinant Antibodies, held in Dublin, Ireland. Dr. Agamemnon Epenetos, Access' Chief Scientific Officer -- Europe, presented data showing that Angiolix has the potential to prevent the growth of cancer stem cells.

Dr. Epenetos commented, "There is a growing body of evidence that indicates that tumor progression, dissemination and metastases result from cancer stem cells rather than the other cells which form the bulk of a cancer. As a result, therapies which attack these tumor cells will delay the onset of progression, but rarely cure the disease. Cancer stem cells are a subgroup of cancer cells that can be resistant to standard treatments, so agents like Angiolix, which have the potential to thwart cancer stem cells, hold great promise for the future treatment and eradication of cancer."

Access' monoclonal antibody product, Angiolix, blocks angiogenesis by inhibiting a novel receptor called lactadherin. Lactadherin causes angiogenesis through a VEGF dependent mechanism. Several other drugs have been developed or are in development to block VEGF and VEGF induced angiogenesis, such as Avastin.

In the presentation, Dr. Epenetos showed that Angiolix has been shown not only to block new blood vessels in tumors, in a similar manner to other anti VEGF drugs like Avastin, but that it could additionally have a direct killing effect on tumor cells potentially including cancer stem cells that are involved in angiogenesis and metastasis.

Access Pharmaceuticals is currently conducting key preclinical studies at Imperial College London, UK to assess the efficacy of Angiolix in a wide range of tumor models. These studies aim to demonstrate the potential efficacy of Angiolix as a monotherapy and in com
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
2. A Perfect Storm Threatens Patient Access to Specialty Medical Care
3. AMT Makes Important Advance in the Development of its Gene Therapy for Hemophilia B -Company Accesses Technology to Prevent Immune Response
4. Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region
5. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
6. AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy
7. Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. SurgiQuest Announces First Single Port Procedure for Ovary Removal Using AirSeal(TM) Access System
9. Scientists call for more access to biotech crop data
10. Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability
11. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TS...d that John Docherty, president and chief operatin...6th annual Investor Summit on November 10, 2009 at...r. Docherty will provide an overview of the Compan...nd Topical Interferon Alpha-2b. The slide show po...
(Date:11/6/2009)... ,, 3Q09 Corporate...a(TM) E.U. Marketing Authorization to Astellas Pha...mercial readiness activities Expanded management ...ng; and Director, Commercial Operations Appointed...t Committee chairman , Upcoming 2009 Milest...
(Date:11/6/2009)...PRNewswire/ -- Intarcia Therapeutics, Inc. deliver...#174; continuous delivery of exenatide) program fo...nual Diabetes Technology Meeting in San Francisco,...prnh/20050301/SFTU126LOGO ) ,, Continuous Sub...s Plasma Glucose, HbA1c and Reduces Weight in a 28...
(Date:11/5/2009)... GenVec, Inc. (Nasdaq: ...he third quarter ended September 30, 2009. GenVec ...re) for the three months ended September 30, 2009 ...share) in the comparable quarter of 2008. For the ... loss was $14.1 million ($0.15 per share), compare...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
...ns, and great differences among countries. This i...to use previously collected samples from biobanks ...xtremely complicated to carry out major internatio...hnology, Swedish ethics researchers at the Center ... researchers, put forward a pioneering solution: a...
...w kind of biosensor can tell., A new and deceptiv...s at Vanderbilt University that can measure the in...ical molecules including proteins, sugars, antibod...capability needed to capitalize on the new avenues...ar-plus effort to sequence the human genome. DNA i...
...ound that the body,s innate ability to adapt to re...effective and less costly artificial respirators. ...nduced sedation or paralysis currently necessary f...associative learning, or our innate ability to ada...e described in the September 12 issue of PLoS ONE,...
Other Biology Technology:Long-awaited international ethical guidelines for biobank researchers 2When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell 2When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell 3MIT: Leveraging learning for artificial respiration 2
(Date:11/9/2009)...ing Harbor, N.Y. Oncologists have had their hands...have mutations that disable a protein called p53. ...s several cancer-fighting operations within cells.... often cannot be treated. , These tumors might ...ew study from Cold Spring Harbor Laboratory (CSHL)...
(Date:11/9/2009)...versity evolutionary biologists David Queller and ...peration and low conflict between components, from..."organismality," whether that thing is an animal, ...traits scientists use to describe an organism, suc...species, may not be necessary to achieve organisma...
(Date:11/9/2009)...f academic, government and industry researchers ha...esculenta) genome. The project is an important fir...is subsistence crop and addressing some of the man... world. , Cassava is a root crop that serves as ...people each day. Although it has many properties t...
Breaking Biology News(10 mins):CSHL study shows that some malignant tumors can be shut down after all 2CSHL study shows that some malignant tumors can be shut down after all 3What is the meaning of 'one'? 2What is the meaning of 'one'? 3Researchers complete draft genome sequence for cassava 2Researchers complete draft genome sequence for cassava 3Researchers complete draft genome sequence for cassava 4Injection May Heal Damaged Heart 52560 1Injection May Heal Damaged Heart 52560 2National Science Foundation Announces 2420M Research Award to South Carolina 52556 1National Science Foundation Announces 2420M Research Award to South Carolina 52556 2National Science Foundation Announces 2420M Research Award to South Carolina 52556 3More than 1 000 Underinsured and Uninsured Individuals Receive Free Dental Care 52553 1More than 1 000 Underinsured and Uninsured Individuals Receive Free Dental Care 52553 2
...) In an epidemiological study, Tufts University re...in a sample of the United States population based...LP) levels in the bloodstream. Plasma PLP is the i... current Recommended Dietary Allowance (RDA) of vi...function and important for maintaining a healthy i...
...reproduce, like all vertebrates, they either lay t... according to new research by a team of Boston Uni...ropsophus ebraccatus) in Panama that reproduces bo...ecision to lay egg masses aquatically in a pond or...ond, where the newly-hatched tadpoles simply fall ...
...quality at beaches along the Great Lakes have prom... safe for recreation. A new collaborative project ...rs when they are faced with deciding whether to cl...rative effort will draw on the expertise of U.S. G...l agencies. , The project has been funded throug...
Other Biology News:Study identifies trends of vitamin B6 status in US population sample 2Study identifies trends of vitamin B6 status in US population sample 3Reproductive plasticity revealed: Neotropical treefrog can choose to lay eggs in water or on land 2To swim or not to swim? 2
ProtoArray Kinase Substrate Identification Application Kit from Invitrogen
Yeast Extract Solution from Invitrogen
GIBCO Dulbeccos Modified Eagle Medium (D-MEM) (1X); powder (low glucose) from Invitrogen
Rabbit Anti-CUGBP2 Monoclonal Antibody, Unconjugated, Clone PADZMD.495 from Invitrogen
Biology Products: